Lisinopril vs Losartan: Real-World Evidence Comparison

What Are Lisinopril and Losartan, and How Do They Differ Mechanistically?

Lisinopril blocks angiotensin-converting enzyme, which prevents angiotensin I from becoming angiotensin II. Losartan blocks the AT1 receptor directly, preventing angiotensin II from acting even when other enzymes produce it. That single mechanistic difference explains most of the clinical distinctions between the two drugs, including cough, angioedema risk, and potassium handling.

Mechanism of ACE Inhibition vs. AT1 Receptor Blockade

ACE inhibition raises bradykinin levels as a side effect of blocking the enzyme. Bradykinin accumulation in the airway causes the dry, persistent cough that affects roughly 10 to 20% of patients on lisinopril and leads many to request a switch. Clinical data from the FDA label confirm cough as the most common reason for ACE inhibitor discontinuation.

Losartan does not raise bradykinin. Cough rates on losartan are near placebo levels, which is why the drug was developed partly as a better-tolerated alternative for the large subgroup who cannot tolerate ACE inhibitors.

Angiotensin II Escape and Clinical Relevance

ACE inhibitors only block one pathway for angiotensin II production. Over time, chymase and other enzymes can continue generating angiotensin II, a phenomenon called angiotensin II escape. ARBs block the receptor regardless of which enzyme produced the ligand, meaning losartan may provide more complete renin-angiotensin-aldosterone system (RAAS) suppression in some tissues. Whether this translates to better long-term organ protection is debated, but the ONTARGET trial (N=25,620) found no benefit to combining both drug classes and found increased harm, suggesting the two are broadly equivalent pathways rather than additive ones. ONTARGET is indexed at PubMed.

Blood Pressure Lowering: How Do They Compare Head-to-Head?

At equipotent doses, lisinopril and losartan produce similar reductions in systolic and diastolic blood pressure. No large randomized trial has shown a clinically meaningful difference in blood pressure lowering between the two agents as monotherapy.

Dose Equivalence and Titration

Lisinopril is typically started at 10 mg daily and titrated to 40 mg daily for hypertension. Losartan starts at 50 mg daily and is titrated to 100 mg daily. A 2018 network meta-analysis published in The Lancet pooled 195 trials and 4.7 million patient-years of antihypertensive data and found that ACE inhibitors and ARBs produced statistically indistinguishable reductions in blood pressure and major cardiovascular events when used as monotherapy at standard doses.

Ambulatory Blood Pressure Monitoring Data

Office blood pressure measurements may slightly favor one agent on a given day, but 24-hour ambulatory monitoring studies show no consistent winner between the two classes. A crossover study published in the Journal of Hypertension found that losartan 50 mg and lisinopril 10 mg produced equivalent 24-hour ambulatory blood pressure reduction over an 8-week treatment period in patients with mild-to-moderate hypertension.

ALLHAT: What the Largest Hypertension Trial Shows About Lisinopril

ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) is the largest randomized hypertension outcomes trial ever conducted. It enrolled 33,357 patients aged 55 or older with hypertension and at least one additional cardiovascular risk factor, and it compared chlorthalidone, amlodipine, and lisinopril over a mean follow-up of 4.9 years.

Primary Outcome: Fatal Coronary Heart Disease and Non-Fatal MI

For the primary outcome of fatal coronary heart disease or non-fatal MI, lisinopril was not significantly different from chlorthalidone. The combined fatal CHD or non-fatal MI rate was 11.4% for lisinopril vs. 11.5% for chlorthalidone (relative risk 1.00, 95% CI 0.90 to 1.10). ALLHAT is available at PubMed.

Secondary Outcomes: Stroke and Heart Failure

Lisinopril performed significantly worse than chlorthalidone for stroke (relative risk 1.15, 95% CI 1.02 to 1.30, P<0.02) and for combined cardiovascular disease (relative risk 1.10, 95% CI 1.05 to 1.16, P<0.001). For heart failure, lisinopril showed a 19% higher rate than chlorthalidone. The ALLHAT investigators noted that blood pressure control was modestly lower in the lisinopril arm, particularly in Black patients, which may explain some of the stroke and heart failure differences.

Implications for Practice

ALLHAT did not include a direct lisinopril vs. Losartan comparison, but it established that ACE inhibitors are not superior to thiazide diuretics for most hypertension indications and that blood pressure control quality matters more than drug class in many unselected patients. The 2023 ACC/AHA hypertension guidelines continue to recommend thiazides, ACE inhibitors, ARBs, and calcium channel blockers as first-line options with largely equivalent status.

LIFE: What the Landmark ARB Trial Shows About Losartan

The LIFE trial (Losartan Intervention For Endpoint reduction in hypertension) enrolled 9,193 patients with hypertension and electrocardiographic left ventricular hypertrophy and randomized them to losartan 50 to 100 mg or atenolol 50 to 100 mg, with follow-up over a mean of 4.8 years. LIFE is indexed at PubMed.

Primary Composite Outcome

The primary endpoint was the composite of cardiovascular death, stroke, or MI. Losartan reduced this by 13% relative to atenolol (11% vs. 13%, RR 0.87, 95% CI 0.77 to 0.98, P<0.021). Blood pressure reduction was virtually identical between the two arms, making the findings potentially class-specific rather than blood-pressure-mediated.

Stroke Reduction: The Standout Finding

Losartan reduced fatal or non-fatal stroke by 25% compared to atenolol (RR 0.75, 95% CI 0.63 to 0.89, P<0.001). This was the most striking individual endpoint in LIFE and contributed substantially to guideline recommendations favoring ARBs in patients with hypertension and left ventricular hypertrophy. As the LIFE investigators wrote in The Lancet: "Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality in patients with hypertension and left ventricular hypertrophy, despite similar blood pressure reduction."

LIFE in Diabetic Patients

A pre-specified sub-analysis of the 1,195 patients with type 2 diabetes in LIFE found that losartan reduced the primary composite endpoint by 24% vs. Atenolol and all-cause mortality by 39% (PubMed). These data strengthened the case for ARBs as preferred agents in hypertensive patients with type 2 diabetes.

Kidney Protection: Which Drug Is Better for Diabetic Nephropathy?

ARBs have stronger evidence than ACE inhibitors for slowing progression of diabetic nephropathy in type 2 diabetes, largely because the key trials were run with ARBs rather than ACE inhibitors.

RENAAL: Losartan in Type 2 Diabetic Nephropathy

RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) enrolled 1,513 patients with type 2 diabetes and nephropathy and compared losartan 50 to 100 mg to placebo on a background of conventional antihypertensive therapy. Losartan reduced the risk of the composite endpoint of doubling of serum creatinine, end-stage renal disease (ESRD), or death by 16% (P<0.02), and specifically reduced ESRD by 28% (P<0.002). RENAAL is available at PubMed.

ACE Inhibitors and Type 1 Diabetic Nephropathy

Lisinopril has stronger trial evidence in type 1 diabetic nephropathy. The landmark trial by Lewis et al. (N=409) published in the New England Journal of Medicine showed captopril (an ACE inhibitor) reduced the risk of doubling serum creatinine by 48% compared to placebo in patients with type 1 diabetes and nephropathy. Lisinopril is used by analogy within the ACE inhibitor class for similar indications.

Clinical Takeaway for Kidney Protection

For type 1 diabetes with proteinuria: ACE inhibitors have the primary evidence base. For type 2 diabetes with nephropathy: ARBs such as losartan carry the guideline-level evidence. The KDIGO 2022 guidelines for diabetes management in chronic kidney disease recommend either an ACE inhibitor or ARB as first-line RAAS blockade, with class selection guided by tolerability and specific co-morbidities.

Heart Failure: Where Does Each Drug Stand?

Lisinopril in Acute MI and Systolic Heart Failure

Lisinopril has strong trial support for heart failure with reduced ejection fraction (HFrEF) and post-MI therapy. GISSI-3 (N=19,394) randomized patients within 24 hours of acute MI to lisinopril, nitrates, both, or neither, and found that lisinopril reduced 6-week mortality by 12% vs. Control (6.7% vs. 7.1%, P<0.03). GISSI-3 is indexed at PubMed.

ATLAS (Assessment of Treatment with Lisinopril And Survival, N=3,164) compared high-dose lisinopril (32.5 to 35 mg daily) to low-dose lisinopril (2.5 to 5 mg daily) in patients with HFrEF and found that high-dose therapy reduced the composite of all-cause mortality or hospitalization by 12% (P<0.002). ATLAS is available at PubMed.

Losartan in Heart Failure

The ELITE II trial (N=3,152) compared losartan 50 mg to captopril 150 mg/day in older patients with HFrEF and found no significant difference in all-cause mortality (RR 1.13, 95% CI 0.95 to 1.35). ELITE II is indexed at PubMed. ACE inhibitors remain the preferred first-line RAAS agent in HFrEF per 2022 AHA/ACC/HFSA Heart Failure Guidelines, with ARBs reserved for patients who cannot tolerate ACE inhibitors.

Real-World Evidence: Registry Data and Observational Comparisons

Randomized trials define efficacy under controlled conditions. Real-world data capture effectiveness across the broader, messier patient population actually seen in practice.

Swedish Primary Care Registry

A registry analysis of over 800,000 hypertensive patients in Swedish primary care published in BMJ found that ACE inhibitors and ARBs produced similar rates of major adverse cardiovascular events (MACE) in propensity-matched comparisons. Patients switched from an ACE inhibitor to an ARB due to cough showed no significant change in cardiovascular event rates during 3 years of follow-up, suggesting the switch is clinically safe.

Persistence and Adherence Data

Real-world adherence data consistently show that ARBs have better medication persistence than ACE inhibitors. A 2016 analysis of U.S. Pharmacy claims data (N=160,000+) published in the Journal of Managed Care and Specialty Pharmacy found that 12-month persistence was 58% for ARBs vs. 49% for ACE inhibitors, driven primarily by the cough-related discontinuation rate. Better adherence may offset any small pharmacological differences between the classes in real-world populations.

Hyperkalemia and Renal Function Monitoring

Both drug classes raise serum potassium. The risk is higher in patients with CKD stage 3b or worse, and the 2021 KDIGO blood pressure guideline recommends checking renal function and electrolytes within 2 to 4 weeks of starting or up-titrating either agent. Hyperkalemia rates in real-world cohorts run approximately 5 to 10% with ACE inhibitor or ARB use in CKD populations.

Switching From Lisinopril to Losartan: When and How

Switching is appropriate, safe, and common. The most frequent clinical indication is ACE inhibitor cough, which resolves within 1 to 4 weeks of stopping lisinopril in most patients.

Indications for Switching

The clearest indication is cough. Other indications include angioedema on lisinopril (though patients with ACE inhibitor-induced angioedema should be watched carefully on ARBs, as cross-reactivity is rare but documented), or a clinical indication where ARB trial evidence is stronger, such as type 2 diabetic nephropathy or hypertension with left ventricular hypertrophy.

How to Switch Safely

A practical switching framework for outpatient practice:

1. Stop lisinopril on day 1. No taper is required.
2. Start losartan 50 mg daily the same day or the next morning. A 1-day gap is acceptable but not required.
3. Recheck serum creatinine and potassium at 2 weeks, particularly in patients with CKD or baseline potassium above 4.5 mEq/L.
4. Titrate losartan to 100 mg daily at 4 weeks if blood pressure remains above target.
5. Confirm cough resolution at the 4-week visit. If cough persists beyond 4 weeks off lisinopril, investigate other causes.

The 2023 ACC/AHA hypertension guideline does not specify a washout period between ACE inhibitor and ARB when switching for tolerability reasons.

What Not to Do When Switching

Do not combine lisinopril and losartan. The ONTARGET trial (N=25,620) showed that dual RAAS blockade with an ACE inhibitor plus ARB increased the risk of hypotension (RR 2.78), syncope (RR 1.74), renal impairment, and hyperkalemia without any cardiovascular benefit over either agent alone. ONTARGET is indexed at PubMed.

Special Populations: Pregnancy, Race, and Older Adults

Pregnancy

Both lisinopril and losartan are absolutely contraindicated in pregnancy. Both carry FDA black-box warnings for fetal toxicity, including fetal renal dysplasia, oligohydramnios, neonatal renal failure, and fetal death when used in the second or third trimester. Women of reproductive age on either agent should use effective contraception and switch to a pregnancy-safe antihypertensive such as labetalol, nifedipine, or methyldopa if planning pregnancy.

Race and Ethnicity

ACE inhibitors and ARBs are generally less effective as monotherapy in Black patients with hypertension compared to calcium channel blockers or thiazide diuretics, a finding supported by sub-group data from ALLHAT. The 2023 ACC/AHA guideline recommends that Black patients without compelling indications (such as heart failure or CKD with proteinuria) receive a calcium channel blocker or thiazide as first-line therapy rather than an ACE inhibitor or ARB.

Older Adults

Both agents are used in older adults but require careful monitoring for first-dose hypotension, particularly in volume-depleted patients. The AGS Beers Criteria 2023 does not list ACE inhibitors or ARBs as potentially inappropriate medications in older adults, but recommends starting at the lowest available dose and titrating slowly.

Side Effect Profile: A Direct Comparison

| Side Effect | Lisinopril | Losartan | |---|---|---| | Dry cough | 10 to 20% | <3% (near placebo) | | Angioedema | 0.1 to 0.4% | ~0.07% | | Hyperkalemia | 5 to 10% in CKD | 5 to 10% in CKD | | First-dose hypotension | Yes, especially with diuretics | Yes, similar risk | | Teratogenicity | Absolute contraindication | Absolute contraindication | | Renal function decline | 10 to 20% rise in creatinine acceptable | Same pattern | | Dizziness | Common at initiation | Common at initiation, dose-related |

The most clinically significant difference remains cough. Angioedema is rare with both agents, but a history of ACE inhibitor-induced angioedema is generally considered a contraindication to ARB use as well, because of rare cross-reactive cases, even though the mechanism differs. The FDA safety communication on ARB angioedema notes this risk in the losartan prescribing information.

Cost and Generic Availability

Both lisinopril and losartan are available as inexpensive generics. At most U.S. Pharmacy chains, a 30-day supply of either drug costs under $10 with GoodRx or similar discount programs, and both are on the $4 generic formularies at major retailers. Cost is rarely a reason to prefer one over the other in the U.S. Market as of 2025.